Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms ASSURE; ASSURE-1
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
    • 30 Aug 2017 Results assessing impact of apabetalone on attenuated coronary atherosclerotic plaque presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results (n=499) of analysis assessing impact of apabetalone on the neutrophil to lymphocyte ratio and its association with MACE using patient data pooled from SUSTAIN and ASSURE trilas presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top